Interlenkin-2 alone and in combination with other cytokines in melanoma: the investigational approach at the University of Texas M. D. Anderson Cancer Center

D. R. Parkinson, M. Talpaz, K. H. Lee, S. Legha, A. B. Markowitz, K. Itoh, C. M. Balch, J. L. Murray, A. A. Zukiwski, R. S. Benjamin, J. U. Gutterman

    Research output: Contribution to journalArticlepeer-review

    4 Scopus citations

    Abstract

    The clinical data that have been accumulated so far suggests a significant influence of IL-2 dose and schedule on the immunobiological effects and clinical toxicities observed with this cytokine. Consequently, the series of Phase I and Phase II clinical trials conducted at the University of Texas M. D. Anderson Cancer Center in patients with advanced malignant melanoma investigating the use of IL-2 in combination with other cytokines, monoclonal antibodies, or ex vivo activated effector cells have used a common dose and schedule of IL-2 administration for which abundant immunobiological information already exists. This approach allows cross-trial comparison of experience with toxicities, immunobiological observations and clinical activity by a group of investigatiors within a single institution, and more rapid and valid evolution towards combination biological therapy, which preclinical data suggest will have greater activity than single agent therapy.

    Original languageEnglish (US)
    Pages (from-to)39-48
    Number of pages10
    JournalCancer Treatment Reviews
    Volume16
    Issue numberSUPPL. A
    DOIs
    StatePublished - Jun 1989

    ASJC Scopus subject areas

    • Oncology
    • Radiology Nuclear Medicine and imaging

    Fingerprint Dive into the research topics of 'Interlenkin-2 alone and in combination with other cytokines in melanoma: the investigational approach at the University of Texas M. D. Anderson Cancer Center'. Together they form a unique fingerprint.

    Cite this